Skip to content

Preservation of Ovarian Cortex Tissue in Girls With Turner Syndrome

Preservation of Ovarian Cortex Tissue in Girls With Turner Syndrome

Status
Active, not recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03381300
Enrollment
106
Registered
2017-12-21
Start date
2018-01-01
Completion date
2071-11-01
Last updated
2025-02-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Fertility Preservation, Live Birth, Ovarian Tissue Cryopreservation, Premature Ovarian Failure, Turner Syndrome

Brief summary

Rationale: Infertility due is a major concern for girls with Turner syndrome (TS) and their parents. Physicians are often asked about possible options to preserve their fertility. However, despite some experimental case reports, clear evidence for fertility preservation in these girls is lacking and many questions remain. Without evidence on the effectiveness of fertility preservation it cannot routinely be offered to girls with TS. Objective: To investigate the occurrence of live birth in women with TS after ovarian tissue cryopreservation in childhood followed by auto transplantation in adulthood. Study design: A national multicentre exploratory intervention study Study population: Girls diagnosed with Turner Syndrome, aged 2-18 years. Intervention: Ovarian tissue cryopreservation in childhood followed by auto transplantation in adulthood. In order to obtain the ovarian tissue for cryopreservation, all girls must undergo a laparoscopy under general anaesthesia which will be performed in academic/university clinics with paediatric surgery. During the laparoscopic intervention, a unilateral oophorectomy will be performed, thereby leaving the other ovary intact for hormone production, ovulation, spontaneous pregnancies and as an auto transplantation site for cryopreserved-thawed ovarian cortical tissue later on. Furthermore, a small sample of the ovarian cortex will be used to assess the oocyte quality and genetics (e.g. the presence of germ line mosaicism). Oocytes will be karyotyped by using Fluorescence in situ hybridization (FISH). Karyotypic and hormonal data will be collected once at the yearly clinical visit at the paediatric-endocrinologist. Therefore, a buccal swab and one extra blood sample will be taken and evaluated during the routine laboratory evaluation. In the future, auto transplantation of frozen-thawed ovarian cortex strips will be performed.

Detailed description

Nature and extent of the burden and risks associated with participation, benefit and group relatedness: The primary objective remains to preserve the fertility of the respective (minor) patient, facing a very high risk of premature ovarian insufficiency (POI) of 95-98%. Disadvantages of participating in this study are the potential risk of complications related to the laparoscopic unilateral oophorectomy and/or the unknown effect on future fertility of these girls. Moreover, the procedure might raise false hope in patients (and/or parents) about the chance of getting pregnant after auto transplantation of cryopreserved-thawed ovarian tissue in the future. However, we attempt to overcome this by extensive and objective information provision by both written materials and face to face counselling.

Interventions

Laparoscopic unilateral oophorectomy followed by cryopreservation of ovarian cortex tissue

Sponsors

Radboud University Medical Center
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
2 Years to 18 Years
Healthy volunteers
No

Inclusion criteria

In order to be eligible to participate in this study, a subject must meet all of the following criteria: * Girls and young females with classic Turner (i.e. 45X monosomy) or Turner variants (e.g. 45X / 46XX mosaicism, ring X mosaicism, isochromosome X), * Aged 2 through 18 years, * who completed the diagnostic work up phase of TS including routine cardiac screening\*, * whose agreement to participate in this study has been signed by the parents (girls 2-11 years old), * whose agreement to participate in this study has been signed by the patient and her parents (girls 12-17 years old), * whose agreement to participate in this study has been signed by the patient (adolescents of 18 years old).

Exclusion criteria

A potential subject who meets any of the following criteria will be excluded from participation in this study: * Contra-indications for laparoscopic unilateral oophorectomy under general anaesthesia (e.g. severe cardiovascular comorbidity and/or BMI \>40 kg/m2)\*, * Contra-indications for cryopreservation (i.e. active HIV, hepatitis-B or hepatitis-C infection) * Based on the international Cincinnati Turner Guideline consensus Meeting, July 2016 and consultation of Dutch cardiologists, paediatric-cardiologists and anaesthesists between 2016-2017 there are no absolute cardiovascular contra-indications for surgical intervention and/or pregnancy. Advice against surgical intervention and/or pregnancy should be based on the patient-specific cardiovascular risk profile. The 2% mortality risk due to acute aortic dissection is based on one survey and literature review study that reported the outcomes of 101 pregnancies in patients with TS after oocyte donation. Only 50% of the patients were screened by a cardiologist before entering the oocyte donation programme. Therefore, all girls who want to participate in this study should have completed the diagnostic work up phase of TS including routine cardiac screening and will be screened by a paediatric anaesthesist. Exclusion will be based on the patient specific risk profile. See: References.

Design outcomes

Primary

MeasureTime frameDescription
Live birth ratio (LBR) (main outcome)Up to 3 years after auto transplantation of cryopreserved-thawed ovarian cortical tissue, and up to 45 years after ovarian tissue cryopreservation.• Live birth after auto transplantation of cryopreserved-thawed ovarian cortical tissue (i.e. live birth rate or LBR)
Number of primordial follicles (proximate)Within 1 month after ovarian tissue cryopreservationThe number of primordial follicles found in the ovarian tissue

Secondary

MeasureTime frameDescription
Patient's age versus LBRUp to 3 years after auto transplantation of cryopreserved-thawed ovarian cortical tissue, and up to 45 years after ovarian tissue cryopreservation.The association between patient's age at cryopreservation and LBR
Patient's genotype versus LBRUp to 3 years after auto transplantation of cryopreserved-thawed ovarian cortical tissue, and up to 45 years after ovarian tissue cryopreservation.The association between patient's genotype and LBR
Patient's Anti-Müllerian hormone (AMH) level versus LBRUp to 3 years after auto transplantation of cryopreserved-thawed ovarian cortical tissue, and up to 45 years after ovarian tissue cryopreservation.The association between patient's AMH level at cryopreservation and LBR
Patient's Follicle-stimulating hormone (FSH) level versus LBRUp to 3 years after auto transplantation of cryopreserved-thawed ovarian cortical tissue, and up to 45 years after ovarian tissue cryopreservation.The association between patient's FSH level at cryopreservation and LBR

Other

MeasureTime frameDescription
Complication rateUp to 1 year after the laparoscopic procedureThe number of complications related to the laparoscopic procedure
Influence of laparoscopic oophorectomy on puberty and/or menarcheUp to 10 years after the laparoscopic procedureThe incidence of puberty and/or menarche after laparoscopic oophorectomy
Incidence of spontaneous pregnanciesUp to 45 years after the laparoscopic procedureThe incidence of spontaneous pregnancies after laparoscopic oophorectomy
Restoration of ovarian function after auto transplantation of ovarian tissueUp to 2 years after auto transplantation of cryopreserved-thawed ovarian cortical tissueThe incidence of menstruation cycle recovery after auto transplantation of cryopreserved-thawed ovarian tissue in the future
Study participation rateUp to 3 years after inclusionThe willingness of girls with TS to perform a unilateral oophorectomy for fertility preservation (i.e. the study participation rate)
Ongoing pregnancies after auto transplantation of ovarian tissueUp to 2 years and 3 months after auto transplantation of cryopreserved-thawed ovarian cortical tissueThe incidence of ongoing pregnancies after auto transplantation of cryopreserved-thawed ovarian tissue in the future
Miscarriages after auto transplantation of ovarian tissueUp to 3 years after auto transplantation of cryopreserved-thawed ovarian cortical tissueThe number of miscarriages after auto transplantation of cryopreserved-thawed ovarian tissue in the future
Time to pregnancy after auto transplantation of ovarian tissueUp to 2 years after auto transplantation of cryopreserved-thawed ovarian cortical tissueTime to pregnancy after auto transplantation of cryopreserved-thawed ovarian tissue in the future
Time to live birth after auto transplantation of ovarian tissueUp to 3 years after auto transplantation of cryopreserved-thawed ovarian cortical tissueTime to live birth after auto transplantation of cryopreserved-thawed ovarian tissue in the future
Pregnancies after auto transplantation of ovarian tissueUp to 2 years after auto transplantation of cryopreserved-thawed ovarian cortical tissueThe incidence of pregnancies after auto transplantation of cryopreserved-thawed ovarian tissue in the future
Eligible participantsUp to 3 years after inclusionThe number of eligible participants
AgeUp to 3 years after inclusionThe age of the participant
Buccal cells versus peripheral lymphocytesUp to 3 years after inclusionThe incidence of somatic mosaicism (i.e. buccal cells versus peripheral lymphocytes)
Ovarian cells versus peripheral lymphocytesUp to 3 years after inclusionThe incidence of germ cell mosaicism (i.e. ovarian cells versus peripheral lymphocytes and buccal cells)
Serum hormone levelsUp to 3 years after inclusionSerum hormone levels (i.e. FSH, Luteinizing hormone (LH), AMH, E2, inhibin B)

Countries

Netherlands

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 21, 2026